Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma-Reference-Cited by-同舟云学术

Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma

Published:2014-08-17 Issue:4 Volume:20 Page:196-202
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Arai Yasuyuki¹,Yamashita Kouhei¹,Mizugishi Kiyomi¹,Nishikori Momoko¹,Hishizawa Masakatsu¹,Kondo Tadakazu¹,Kitano Toshiyuki¹,Kawabata Hiroshi¹,Kadowaki Norimitsu¹,Takaori-Kondo Akifumi¹

Affiliation:

1. Department of Hematology and OncologyGraduate School of Medicine, Kyoto University, Kyoto, Japan

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1179/1607845414Y.0000000188

Reference29 articles.

1. The mechanisms of action of rituximab in the elimination of tumor cells

2. A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma

3. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics

4. B-cell depletion in the treatment of lupus nephritis

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis;Internal Medicine;2024

2. Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab;Annals of Allergy, Asthma & Immunology;2023-06

3. Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives;Frontiers in Immunology;2022-11-07

4. An Update on the Incidence, Risk Factors and Mechanisms of Rituximab- Associated Neutropenia;Archives of Medical Science;2022-09-15

5. Late-onset toxicities of monoclonal antibodies in cancer patients;Immunotherapy;2022-09